HC Wainwright Forecasts Legend Biotech Q2 Earnings

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Legend Biotech in a research note issued to investors on Thursday, July 17th. HC Wainwright analyst M. Kapoor expects that the company will earn ($0.08) per share for the quarter. HC Wainwright has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech's Q3 2025 earnings at $0.24 EPS, Q4 2025 earnings at $0.46 EPS, FY2025 earnings at $0.10 EPS, Q2 2026 earnings at $0.30 EPS and FY2026 earnings at $1.64 EPS.

A number of other brokerages also recently commented on LEGN. Morgan Stanley restated an "overweight" rating and set a $81.00 price objective (up previously from $80.00) on shares of Legend Biotech in a research report on Thursday, July 10th. Truist Financial cut their price objective on shares of Legend Biotech from $88.00 to $71.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Royal Bank Of Canada restated an "outperform" rating and set a $84.00 price objective on shares of Legend Biotech in a research report on Tuesday, April 22nd. Johnson Rice restated a "buy" rating on shares of Legend Biotech in a research report on Thursday. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $55.00 price objective on shares of Legend Biotech in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $73.33.

Legend Biotech Price Performance

Legend Biotech stock opened at $41.59 on Monday. Legend Biotech has a 12 month low of $27.34 and a 12 month high of $60.87. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.20 and a quick ratio of 5.07. The business has a 50 day simple moving average of $33.81 and a 200-day simple moving average of $34.43. The stock has a market capitalization of $7.64 billion, a PE ratio of -70.49 and a beta of 0.19.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.33. Legend Biotech had a negative net margin of 29.95% and a negative return on equity of 21.19%. The firm had revenue of $195.05 million during the quarter, compared to the consensus estimate of $190.83 million. During the same quarter in the prior year, the firm earned ($0.16) EPS. Legend Biotech's revenue for the quarter was up 107.8% on a year-over-year basis.

Institutional Investors Weigh In On Legend Biotech

A number of large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. grew its stake in Legend Biotech by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,092 shares of the company's stock valued at $71,000 after acquiring an additional 377 shares during the last quarter. Rhumbline Advisers grew its stake in Legend Biotech by 1.4% in the 1st quarter. Rhumbline Advisers now owns 28,029 shares of the company's stock valued at $951,000 after acquiring an additional 391 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Legend Biotech by 1.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,610 shares of the company's stock valued at $1,887,000 after acquiring an additional 579 shares during the last quarter. GAMMA Investing LLC grew its stake in Legend Biotech by 145.4% in the 1st quarter. GAMMA Investing LLC now owns 1,291 shares of the company's stock valued at $44,000 after acquiring an additional 765 shares during the last quarter. Finally, Shell Asset Management Co. grew its stake in Legend Biotech by 62.0% in the 4th quarter. Shell Asset Management Co. now owns 2,090 shares of the company's stock valued at $68,000 after acquiring an additional 800 shares during the last quarter. 70.89% of the stock is owned by institutional investors and hedge funds.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.